Los Angeles Capital Management & Equity Research Inc. Sells 34,186 Shares of Concert Pharmaceuticals Inc (CNCE)

Los Angeles Capital Management & Equity Research Inc. lowered its stake in Concert Pharmaceuticals Inc (NASDAQ:CNCE) by 62.7% during the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 20,344 shares of the biotechnology company’s stock after selling 34,186 shares during the quarter. Los Angeles Capital Management & Equity Research Inc. owned approximately 0.09% of Concert Pharmaceuticals worth $255,000 as of its most recent filing with the SEC.

Other hedge funds also recently bought and sold shares of the company. Mackenzie Financial Corp purchased a new stake in Concert Pharmaceuticals in the 3rd quarter valued at approximately $160,000. Jefferies Group LLC purchased a new stake in Concert Pharmaceuticals in the 3rd quarter valued at approximately $174,000. MetLife Investment Advisors LLC lifted its stake in Concert Pharmaceuticals by 55.5% in the 3rd quarter. MetLife Investment Advisors LLC now owns 13,953 shares of the biotechnology company’s stock valued at $207,000 after buying an additional 4,980 shares in the last quarter. Capital Fund Management S.A. lifted its stake in Concert Pharmaceuticals by 44.1% in the 3rd quarter. Capital Fund Management S.A. now owns 20,900 shares of the biotechnology company’s stock valued at $310,000 after buying an additional 6,400 shares in the last quarter. Finally, Rhumbline Advisers lifted its stake in Concert Pharmaceuticals by 42.4% in the 4th quarter. Rhumbline Advisers now owns 31,261 shares of the biotechnology company’s stock valued at $392,000 after buying an additional 9,313 shares in the last quarter. 75.73% of the stock is currently owned by hedge funds and other institutional investors.

A number of research firms recently issued reports on CNCE. BidaskClub raised Concert Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Friday, January 4th. Zacks Investment Research upgraded Concert Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Thursday, January 3rd. ValuEngine upgraded Concert Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Wednesday, November 28th. HC Wainwright reiterated a “buy” rating on shares of Concert Pharmaceuticals in a report on Friday, March 1st. Finally, TheStreet downgraded Concert Pharmaceuticals from a “c-” rating to a “d” rating in a report on Friday, March 1st. One analyst has rated the stock with a sell rating, two have given a hold rating, three have issued a buy rating and one has given a strong buy rating to the company. Concert Pharmaceuticals presently has a consensus rating of “Buy” and a consensus target price of $23.00.

Shares of CNCE opened at $16.47 on Friday. The firm has a market capitalization of $387.52 million, a price-to-earnings ratio of -6.86 and a beta of 1.03. Concert Pharmaceuticals Inc has a fifty-two week low of $10.80 and a fifty-two week high of $24.19.

Concert Pharmaceuticals (NASDAQ:CNCE) last issued its quarterly earnings results on Thursday, February 28th. The biotechnology company reported ($0.89) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.74) by ($0.15). Concert Pharmaceuticals had a negative net margin of 533.31% and a negative return on equity of 29.33%. Equities research analysts anticipate that Concert Pharmaceuticals Inc will post -3.32 earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: “Los Angeles Capital Management & Equity Research Inc. Sells 34,186 Shares of Concert Pharmaceuticals Inc (CNCE)” was originally posted by Transcript Daily and is owned by of Transcript Daily. If you are accessing this piece on another domain, it was stolen and republished in violation of United States and international copyright laws. The correct version of this piece can be viewed at https://transcriptdaily.com/2019/03/17/los-angeles-capital-management-equity-research-inc-sells-34186-shares-of-concert-pharmaceuticals-inc-cnce.html.

Concert Pharmaceuticals Company Profile

Concert Pharmaceuticals, Inc operates as a clinical stage biopharmaceutical company. The company discovers and develops novel small molecule drugs for use in the treatment of various pulmonary diseases, including autoimmune and inflammatory diseases, and central nervous systems disorders. Its product candidates include AVP-786, a combination of deudextromethorphan and an ultra-low dose of quinidine, which is in Phase 3 clinical trials for the treatment of neurologic and psychiatric disorders, including agitation associated with Alzheimer's disease; CTP-730, a deuterated analog of apremilast that has completed the Phase 1 clinical trials for the treatment of inflammation or cancer; JZP-386, which has completed the Phase 1 clinical trials for the treatment of patients with narcolepsy; and CTP-543, which is in Phase 1 clinical trials for use in the treatment of alopecia areata.

Featured Article: Google Finance Portfolio Tips and Tricks

Want to see what other hedge funds are holding CNCE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Concert Pharmaceuticals Inc (NASDAQ:CNCE).

Institutional Ownership by Quarter for Concert Pharmaceuticals (NASDAQ:CNCE)

Receive News & Ratings for Concert Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Concert Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.